315 related articles for article (PubMed ID: 28521156)
1. 2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
Li X; Guise CP; Taghipouran R; Yosaatmadja Y; Ashoorzadeh A; Paik WK; Squire CJ; Jiang S; Luo J; Xu Y; Tu ZC; Lu X; Ren X; Patterson AV; Smaill JB; Ding K
Eur J Med Chem; 2017 Jul; 135():531-543. PubMed ID: 28521156
[TBL] [Abstract][Full Text] [Related]
2. Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity.
Vlacic G; Hoda MA; Klikovits T; Sinn K; Gschwandtner E; Mohorcic K; Schelch K; Pirker C; Peter-Vörösmarty B; Brankovic J; Dome B; Laszlo V; Cufer T; Rozman A; Klepetko W; Grasl-Kraupp B; Hegedus B; Berger W; Kern I; Grusch M
Cells; 2019 Sep; 8(9):. PubMed ID: 31527449
[TBL] [Abstract][Full Text] [Related]
3. Discovery and Optimization of a Novel 2
Wei Y; Tang Y; Zhou Y; Yang Y; Cui Y; Wang X; Wang Y; Liu Y; Liu N; Wang Q; Li C; Ruan H; Zhou H; Wei M; Yang G; Yang C
J Med Chem; 2021 Jul; 64(13):9078-9099. PubMed ID: 34129329
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.
Wu L; Zhang C; He C; Qian D; Lu L; Sun Y; Xu M; Zhuo J; Liu PCC; Klabe R; Wynn R; Covington M; Gallagher K; Leffet L; Bowman K; Diamond S; Koblish H; Zhang Y; Soloviev M; Hollis G; Burn TC; Scherle P; Yeleswaram S; Huber R; Yao W
J Med Chem; 2021 Aug; 64(15):10666-10679. PubMed ID: 34269576
[TBL] [Abstract][Full Text] [Related]
5. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
[TBL] [Abstract][Full Text] [Related]
6. Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1-3).
Yamani A; Zdżalik-Bielecka D; Lipner J; Stańczak A; Piórkowska N; Stańczak PS; Olejkowska P; Hucz-Kalitowska J; Magdycz M; Dzwonek K; Dubiel K; Lamparska-Przybysz M; Popiel D; Pieczykolan J; Wieczorek M
Eur J Med Chem; 2021 Jan; 210():112990. PubMed ID: 33199155
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 4,6-pyrimidinediamine derivatives as novel dual EGFR/FGFR inhibitors aimed EGFR/FGFR1-positive NSCLC.
Xie Z; Wu K; Wang Y; Pan Y; Chen B; Cheng D; Pan S; Guo T; Du X; Fang L; Wang X; Ye F
Eur J Med Chem; 2020 Feb; 187():111943. PubMed ID: 31846829
[TBL] [Abstract][Full Text] [Related]
8. Discovery of N-(4-((6-(3,5- Dimethoxyphenyl)-9H-purine derivatives as irreversible covalent FGFR inhibitors.
Wang Y; Pan Y; Lv Z; Gou S
Eur J Med Chem; 2024 May; 271():116415. PubMed ID: 38643670
[TBL] [Abstract][Full Text] [Related]
9. Optimization of 1H-indazol-3-amine derivatives as potent fibroblast growth factor receptor inhibitors.
Cui J; Peng X; Gao D; Dai Y; Ai J; Li Y
Bioorg Med Chem Lett; 2017 Aug; 27(16):3782-3786. PubMed ID: 28687204
[TBL] [Abstract][Full Text] [Related]
10. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.
Liu PCC; Koblish H; Wu L; Bowman K; Diamond S; DiMatteo D; Zhang Y; Hansbury M; Rupar M; Wen X; Collier P; Feldman P; Klabe R; Burke KA; Soloviev M; Gardiner C; He X; Volgina A; Covington M; Ruggeri B; Wynn R; Burn TC; Scherle P; Yeleswaram S; Yao W; Huber R; Hollis G
PLoS One; 2020; 15(4):e0231877. PubMed ID: 32315352
[TBL] [Abstract][Full Text] [Related]
11. Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors.
Brameld KA; Owens TD; Verner E; Venetsanakos E; Bradshaw JM; Phan VT; Tam D; Leung K; Shu J; LaStant J; Loughhead DG; Ton T; Karr DE; Gerritsen ME; Goldstein DM; Funk JO
J Med Chem; 2017 Aug; 60(15):6516-6527. PubMed ID: 28665128
[TBL] [Abstract][Full Text] [Related]
12. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
Tan L; Wang J; Tanizaki J; Huang Z; Aref AR; Rusan M; Zhu SJ; Zhang Y; Ercan D; Liao RG; Capelletti M; Zhou W; Hur W; Kim N; Sim T; Gaudet S; Barbie DA; Yeh JR; Yun CH; Hammerman PS; Mohammadi M; Jänne PA; Gray NS
Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4869-77. PubMed ID: 25349422
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of novel 3-(thiophen-2-ylthio)pyridine derivatives as potential multitarget anticancer agents.
Xi JJ; He RY; Zhang JK; Cai ZB; Zhuang RX; Zhao YM; Shao YD; Pan XW; Shi TT; Dong ZJ; Liu SR; Kong LM
Arch Pharm (Weinheim); 2019 Aug; 352(8):e1900024. PubMed ID: 31338897
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of 4-bromo-N-(3,5-dimethoxyphenyl)benzamide derivatives as novel FGFR1 inhibitors for treatment of non-small cell lung cancer.
Xie Z; Cheng D; Luo L; Shen G; Pan S; Pan Y; Chen B; Wang X; Liu Z; Zhang Y; Ye F
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):905-919. PubMed ID: 29734851
[TBL] [Abstract][Full Text] [Related]
15. Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion.
Kawano S; Kawada MI; Fukushima S; Arai Y; Shibata T; Miyano SW
Anticancer Res; 2024 Jun; 44(6):2393-2406. PubMed ID: 38821585
[TBL] [Abstract][Full Text] [Related]
16. Discovery of LHQ490 as a highly selective fibroblast growth factor receptor 2 (FGFR2) inhibitor.
Li H; Ke R; Zhou Y; Chang S; Wang J; Su C; Wu P; Yang B; Wang Z; Ding K; Ma D
Eur J Med Chem; 2024 Jun; 272():116473. PubMed ID: 38718625
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of biological and antitumor activities of 5,7-dimethyl- oxazolo[5,4-d]pyrimidine-4,6(5H,7H)-dione derivatives as novel inhibitors of FGFR1.
Ye F; Wang Y; Nian S; Wang Y; Chen D; Yu S; Wang S
J Enzyme Inhib Med Chem; 2015 Dec; 30(6):961-6. PubMed ID: 25683078
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
Peng X; Hou P; Chen Y; Dai Y; Ji Y; Shen Y; Su Y; Liu B; Wang Y; Sun D; Jiang Y; Zha C; Xie Z; Ding J; Geng M; Ai J
J Exp Clin Cancer Res; 2019 Aug; 38(1):372. PubMed ID: 31438996
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors.
Fan J; Dai Y; Shao J; Peng X; Wang C; Cao S; Zhao B; Ai J; Geng M; Duan W
Bioorg Med Chem Lett; 2016 Jun; 26(11):2594-9. PubMed ID: 27117427
[TBL] [Abstract][Full Text] [Related]
20. GZD824 overcomes FGFR1-V561F/M mutant resistance in vitro and in vivo.
Jiang K; Tang X; Guo J; He R; Chan S; Song X; Tu Z; Wang Y; Ren X; Ding K; Zhang Z
Cancer Med; 2021 Jul; 10(14):4874-4884. PubMed ID: 34114373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
